RRC ID 54789
著者 Choi H, Magyar CE, Nervina JM, Tetradis S.
タイトル Different duration of parathyroid hormone exposure distinctively regulates primary response genes Nurr1 and RANKL in osteoblasts.
ジャーナル PLoS One
Abstract Parathyroid hormone (PTH) exerts dual effects, anabolic or catabolic, on bone when administrated intermittently or continuously, via mechanisms that remain largely unknown. PTH binding to cells induces PTH-responsive genes including primary response genes (PRGs). PRGs are rapidly induced without the need for de novo protein synthesis, thereby playing pivotal roles in directing subsequent molecular responses. In this study, to understand the role of PRGs in mediating osteoblastic cellular responses to PTH, we investigated whether various durations of PTH differentially induce PRGs in primary osteoblasts and MC3T3-E1. Nurr1 and RANKL, PRGs known for their anabolic and catabolic roles in bone metabolism respectively, presented distinctive transient vs. sustained induction kinetics. Corroborating their roles, maximum induction of Nurr1 was sufficiently achieved by brief PTH in as little as 30 minutes and continued beyond that, while maximum induction of RANKL was achieved only by prolonged PTH over 4 hours. Our data suggested distinctive regulatory mechanisms for Nurr1 and RANKL: PKA-mediated chromatin rearrangement for transcriptional regulation of both PRGs and ERK-mediated transcriptional regulation for RANKL but not Nurr1. Lastly, we classified PRGs into two groups based on the induction kinetics: The group that required brief PTH for maximum induction included Nur77, cox-2, and Nurr1, all of which are reported to play roles in bone formation. The other group that required prolonged PTH for maximum induction included IL-6 and RANKL, which play roles in bone resorption. Together, our data suggested the crucial role of PRG groups in mediating differential osteoblastic cellular responses to intermittent vs. continuous PTH. Continued research into the regulatory mechanisms of PKA and ERK for PRGs will help us better understand the molecular mechanisms underlying the dual effects of PTH, thereby optimizing the current therapeutic use of PTH for osteoporosis.
巻・号 13(12)
ページ e0208514
公開日 2018-12-21
DOI 10.1371/journal.pone.0208514
PII PONE-D-18-19639
PMID 30576321
PMC PMC6303058
MeSH Animals Animals, Newborn Bone Resorption / genetics Bone Resorption / metabolism Cells, Cultured Gene Expression Regulation / drug effects Mice Nuclear Receptor Subfamily 4, Group A, Member 2 / genetics* Nuclear Receptor Subfamily 4, Group A, Member 2 / metabolism Osteoblasts / drug effects* Osteoblasts / metabolism* Osteogenesis / drug effects Osteogenesis / genetics Parathyroid Hormone / pharmacology* RANK Ligand / genetics* RANK Ligand / metabolism Signal Transduction / drug effects Signal Transduction / genetics Time Factors
IF 2.776
引用数 1
リソース情報
ヒト・動物細胞 MC3T3-E1(RCB1126)